Search This Blog

Wednesday, October 14, 2026

First Tracks Biotherapeutics reports positive Phase 1b ANB033 data in celiac disease

 

 showing statistically significant protection against gluten-induced damage and symptoms

  • ANB033 demonstrated a favorable safety profile in the Phase 1b gluten-challenge study in celiac disease patients.
  • First Tracks plans to advance the ANB033 celiac program to late-stage clinical development in 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)